Interim data suggests that LY-CoV555 has a direct antiviral effect and may reduce COVID-related hospitalizations

VANCOUVER, British Columbia–(BUSINESS WIRE)–#AbCellera—AbCellera today announced that interim data from a Phase 2 clinical trial of LY-CoV555, the first antibody to emerge from AbCellera’s collaboration with Eli Lilly and Company (Lilly) to create antibody therapies for the prevention and treatment of COVID-19, shows a reduction in the rate of hospitalization in patients treated with the antibody. Key findings from the interim data of Lilly’s randomized, double-blind, placebo-controlled Phase 2 study, BLAZE-1, are as follows:

• Primary endpoint of viral load change from baseline at day 11 was met for one of three doses; consistent effects of viral reduction seen at earlier time points
• Rate of hospitalizations and ER visits was 1.7 percent (5/302) for LY-CoV555 vs. 6 percent (9/150) for placebo – a 72 percent risk reduction in this limited population
• LY-CoV555 was well-tolerated across all doses with no drug-related serious adverse events reported

“Today’s announcement of the interim result from the BLAZE-1 trial reinforce our confidence in LY-CoV555 as a potential treatment for COVID-19,” said Carl Hansen, Ph.D., CEO of AbCellera. “Our team is grateful for the tireless efforts of the many scientists and clinicians that have made it possible to achieve this milestone so quickly.”

LY-CoV555 is developed from an antibody that was identified from the blood of a recovered COVID-19 patient using AbCellera’s pandemic response platform. Within one week of receiving the sample, AbCellera screened over 5 million antibody-producing cells to identify and isolate approximately 500 unique antibodies that bind to SARS-CoV-2, the virus that causes COVID-19. Together with the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID) and Lilly, those antibodies were tested to find the ones most effective in neutralizing the virus. LY-CoV555 was selected as the lead candidate from this group of antibodies, and is the world’s first therapeutic candidate specifically developed against SARS-CoV-2 to enter human clinical trials.

AbCellera’s pandemic response capabilities were developed over the past two years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen. (Read more…)

About LY-CoV555

LY-CoV555 is a potent, neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus and potentially preventing and treating COVID-19. LY-CoV555 emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

About AbCellera Biologics Inc.

AbCellera is a privately held technology company with an antibody discovery platform that searches and analyzes natural immune systems to find antibodies that can be used to prevent and treat disease. AbCellera’s technology, which combines high-throughput microfluidics, hyper-scale data science, machine learning, bioinformatics, and genomics, identifies new drug candidates and aims to reduce the time it takes to bring treatments to the clinic. AbCellera’s partners include leading biotechnology companies, global health organizations, and many of the top 10 biopharmaceutical companies. For more information, visit www.abcellera.com.

Contacts

Jessica Yingling; [email protected], +1.236.521.6774 (AbCellera Media)

Kevin Heyries; [email protected], +1.604.559.9005 (AbCellera Business Development)

Interim data suggests that LY-CoV555 has a direct antiviral effect and may reduce COVID-related hospitalizations

VANCOUVER, British Columbia–(BUSINESS WIRE)–#AbCellera—AbCellera today announced that interim data from a Phase 2 clinical trial of LY-CoV555, the first antibody to emerge from AbCellera’s collaboration with Eli Lilly and Company (Lilly) to create antibody therapies for the prevention and treatment of COVID-19, shows a reduction in the rate of hospitalization in patients treated with the antibody. Key findings from the interim data of Lilly’s randomized, double-blind, placebo-controlled Phase 2 study, BLAZE-1, are as follows:

• Primary endpoint of viral load change from baseline at day 11 was met for one of three doses; consistent effects of viral reduction seen at earlier time points
• Rate of hospitalizations and ER visits was 1.7 percent (5/302) for LY-CoV555 vs. 6 percent (9/150) for placebo – a 72 percent risk reduction in this limited population
• LY-CoV555 was well-tolerated across all doses with no drug-related serious adverse events reported

“Today’s announcement of the interim result from the BLAZE-1 trial reinforce our confidence in LY-CoV555 as a potential treatment for COVID-19,” said Carl Hansen, Ph.D., CEO of AbCellera. “Our team is grateful for the tireless efforts of the many scientists and clinicians that have made it possible to achieve this milestone so quickly.”

LY-CoV555 is developed from an antibody that was identified from the blood of a recovered COVID-19 patient using AbCellera’s pandemic response platform. Within one week of receiving the sample, AbCellera screened over 5 million antibody-producing cells to identify and isolate approximately 500 unique antibodies that bind to SARS-CoV-2, the virus that causes COVID-19. Together with the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID) and Lilly, those antibodies were tested to find the ones most effective in neutralizing the virus. LY-CoV555 was selected as the lead candidate from this group of antibodies, and is the world’s first therapeutic candidate specifically developed against SARS-CoV-2 to enter human clinical trials.

AbCellera’s pandemic response capabilities were developed over the past two years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen. (Read more…)

About LY-CoV555

LY-CoV555 is a potent, neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus and potentially preventing and treating COVID-19. LY-CoV555 emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

About AbCellera Biologics Inc.

AbCellera is a privately held technology company with an antibody discovery platform that searches and analyzes natural immune systems to find antibodies that can be used to prevent and treat disease. AbCellera’s technology, which combines high-throughput microfluidics, hyper-scale data science, machine learning, bioinformatics, and genomics, identifies new drug candidates and aims to reduce the time it takes to bring treatments to the clinic. AbCellera’s partners include leading biotechnology companies, global health organizations, and many of the top 10 biopharmaceutical companies. For more information, visit www.abcellera.com.

Contacts

Jessica Yingling; [email protected], +1.236.521.6774 (AbCellera Media)

Kevin Heyries; [email protected], +1.604.559.9005 (AbCellera Business Development)